Skip to main content

Table 4 Manganese superoxide dismutase -102 genotype: overall and recurrence-free survivals with adjuvant chemotherapy

From: Association between manganese superoxide dismutase promoter gene polymorphism and breast cancer survival

Genotype Cases Deaths Hazard ratio minimally adjusteda (95% confidence interval) Hazard ratio fully adjustedb (95% confidence interval)
Overall survival 230 75 P for trend = 0.46 P for trend = 0.42
   CC 140 49 1 (reference) 1 (reference)
   CT 73 21 0.83 (0.49–1.38) 0.67 (0.38–1.17)
   TT 17 5 0.81 (0.32–2.04) 1.07 (0.42–2.74)
   CC 140 49 1 (reference) 1 (reference)
   CT + TT 90 26 0.82 (0.51–1.33) 0.73 (0.44–1.22)
Recurrence-free survival 220 85 P for trend = 0.16 P for trend = 0.12
   CC 136 57 1 (reference) 1 (reference)
   CT 68 24 0.79 (0.49–1.28) 0.64 (0.38–1.07)
   TT 16 4 0.55 (0.20–1.52) 0.73 (0.26–2.049)
   CC 136 57 1 (reference) 1 (reference)
   CT + TT 84 28 0.75 (0.47–1.18) 0.65 (0.40–1.05)
  1. CC, homozygous for the wild-type manganese superoxide dismutase gene; CT, heterozygous for the variant genotype; TT, homozygous for the variant genotype. aMinimally adjusted model: age. bFully adjusted model: age, stage with node status at diagnosis, race, estrogen receptor status, and progesterone receptor status.